Evaluation of tacrine hydrochloride (Cognex®) in two parallel-group studies

Acta Neurologica Scandinavica

Volumn 94, Issue SUPPL.165, 1996, Pages 114-122

  Gracon, Stephen I ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Clinical trial; Efficacy; Hepatotoxicity; Safety; Tacrine

Indexed keywords

PLACEBO; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; ARTICLE; COGNITION; DOSE RESPONSE; DRUG EFFECT; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TIME;

AGED; ALZHEIMER DISEASE; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TACRINE; TIME FACTORS;

EID: 0029686944     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1996.tb05881.x     Document Type: Article

References (15)

1. Summers WK, Majovski LV, Marsh GM, Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986: 315: 1241-45.
2. Fitten LJ, Perryman KM, Gross PL, Fine H., Cummins J., Marshall C. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry 1990: 147: 239-42.
3. Davis KL, Thal LJ, Gamzu ER et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992: 327: 1253-59.
4. Chatellier G., Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Br Med J 1990: 300: 495-99.
5. Gauthier S., Bouchard R., Lamontagne A. et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl J Med 1990: 322: 1272-76.
6. Eagger SA, Levy R., Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991: 337: 989-92.
7. Eagger S., Morant N., Levy R., Sahakian B. Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects. Br J Psychiatry 1992: 160: 36-40.
8. Molloy DW, Guyatt GH, Wilson DB, Duke R., Rees L., Singer J. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. Can Med Assoc J 1991: 144: 29-34.
9. Wilcock GK, Surmon DJ, Scott M. et al. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. Age Ageing 1993: 22: 316-24.
10. Farlow M., Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. For the Tacrine Study Group. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992: 268: 2523-29.
11. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. For the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994: 271: 985-91.
12. Kramer-Ginsberg E., Mohs RC, Aryan M. et al. Clinical predictors of course of Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988: 24: 458-62.
13. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994: 271: 992-98.
14. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994: 28: 744-51.
15. Ford JM, Truman CA, Wilcock GK, Roberts CJC. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther 1993: 53: 691-95.